What's in Instituto de Investigacion Sanitaria La Fe's pipeline?

Instituto de Investigacion Sanitaria La Fe has 6 drugs in our index: 3 marketed, 0 filed, 3 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Instituto de Investigacion Sanitaria La Fe's portfolio?

Top competitors by shared drug class: Assaf-Harofeh Medical Center, Azienda Ospedaliero-Universitaria di Modena, C. R. Bard, Central DuPage Hospital, EMD Serono.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/instituto-de-investigacion-sanitaria-la-fe.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Instituto de Investigacion Sanitaria La Fe — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Instituto de Investigacion Sanitaria La Fe pipeline: 3 marketed, 0 filed, 3 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

3 marketed 0 filed 3 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
A (Chloraprep)	A (Chloraprep)	marketed	Topical antiseptic	Bacterial cell membrane and proteins	Infection Prevention / Dermatology
B (Clorhexidine 2%)	B (Clorhexidine 2%)	marketed	Antimicrobial agent / Antiseptic		Infectious Disease / Antisepsis
Bravelle	Bravelle	marketed			Other
Ganirelix 0.25 mg.	Ganirelix 0.25 mg.	phase 3	GnRH antagonist	GnRH receptor	Reproductive Medicine / Fertility
Micronized natural progesterone.	Micronized natural progesterone.	phase 3	Progestin / Natural progesterone	Progesterone receptor (PR)	Gynecology / Reproductive Health
Recombinant choriogonadotropin alfa	Recombinant choriogonadotropin alfa	phase 3	Gonadotropin; recombinant hormone	Luteinizing hormone receptor (LH-R)	Reproductive Medicine / Fertility

Therapeutic area mix

Reproductive Medicine / Fertility · 2
Gynecology / Reproductive Health · 1
Infection Prevention / Dermatology · 1
Infectious Disease / Antisepsis · 1
Other · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Assaf-Harofeh Medical Center · 1 shared drug class
Azienda Ospedaliero-Universitaria di Modena · 1 shared drug class
C. R. Bard · 1 shared drug class
Central DuPage Hospital · 1 shared drug class
EMD Serono · 1 shared drug class
El Shatby University Hospital for Obstetrics and Gynecology · 1 shared drug class
Eugonia · 1 shared drug class
AEterna Zentaris · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Instituto de Investigacion Sanitaria La Fe:

Cite this brief

Drug Landscape (2026). Instituto de Investigacion Sanitaria La Fe — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/instituto-de-investigacion-sanitaria-la-fe. Accessed 2026-05-17.